Board of Directors
The Board of Directors consists of four members:
David Kauffmann (Chairman)
Mr. Kauffmann is founding Managing Partner of European Equity Partners, Board Director of AGC Biologics, and former Chairman of ARTS Biologics. Until the merger with SGS in 2006, he also held the position of Chairman of the Management Board of Aster Cephac. Prior to EEP, David Kauffmann was a Partner of CAI, a North American US$150 million private equity investment fund. Prior to working in private equity and venture capital, David Kauffmann worked for the American Express Bank in London, New York and Copenhagen, in acquisitions and trade finance.
Bo Jesper Hansen
Bo Jesper Hansen has been a member of the Board of Directors since September 2015. Bo Jesper Hansen is currently Chairman of the Board of Directors of Laborie Inc. and KARO Pharma AB, and Innoventa Medica ApS as well as a member of the Board of Directors of Orphazyme A/S (Vice-Chairman), and Ascelia Pharma AB. Bo Jesper Hansen is also a Venture Partner at Wellington Partners Life Science Fund LP, advisor for Aescap 2.0, Nordic Capital, EQT AB; senior business advisor for HBM Ventures Ltd. and Goldman Sachs. In the past five years, Bo Jesper Hansen has been Chairman of the Board of Directors and a member of the Executive Management of Ablynx NV (acquired by Sanofi), Swedish Orphan Biovitrum AB (publ), Chairman of the Board of Directors of Reapplix ApS, Topotarget A/S (publ) (dissolved by merger), Karolinska Development AB (publ) as well as a member of the Board of Directors of Hyperion Therapeutics Inc. (publ) (dissolved following acquisition), Gambro AB (dissolved following acquisition), Inspyr Inc. (publ), Zymenex Holding A/S (dissolved through acquisition), and Mipsalus Holding ApS. During these years, Bo Jesper Hansen has also served as an expert evaluator for FP7-Health-2012 and in 2013 for the European Commission and has been a thesis supervisor for the Faculty of Pharmaceutical Services. Bo Jesper Hansen holds a MD and PhD degree in Medicine from the University of Copenhagen.
Mr. Gullestrup has been with the Clipper Group in the period 1978 till 2013 and is currently Partner in Clipper Group A/S. He served as Chairman of the Board of Danske Færger A/S until 2014. Per Gullestrup serves on the Board of Directors of Center for Rygkirurgi A/S. He holds a number of additional board positions.
Mr. Munch-Hansen has held a number of executive leadership positions in IT and Tele including SEVP for TDC and President for IBM Nordic. He now holds a number of different board positions.
For further interest in Azanta’s specialty pharma products or investigational cancer products, please contact your local representative or Azanta’s head office.